In the past, CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone)
was considered the gold standard treatment for aggressive non-Hodgkin's lymphoma (NHL) …

Rituximab is an anti-CD20 chimeric monoclonal antibody that has shown substantial activity
in indolent non-Hodgkin's lymphoma (NHL). Recent data indicate that the clinical benefits …

Options for treating aggressive non-Hodgkin lymphoma (NHL) have expanded in recent
years. In phase 3 clinical trials, giving rituximab with cyclophosphamide, vincristine …

The prognosis is poor for patients relapsing following treatment with standard chemotherapy
for aggressive non-Hodgkin's lymphoma. High-dose therapy and autologous stem cell …

The most common subtype of aggressive non-Hodgkin's lymphoma is diffuse large B-cell
lymphoma (DLBCL). Diffuse large B-cell lymphoma represents a heterogeneous entity, with …

The Groupe d'Etude des Lymphomes de l'Adulte (GELA) has conducted several phase II
and III studies in patients with aggressive lymphoma, diffuse large B-cell lymphoma …

Diffuse large B-cell lymphoma (DLCL) is the most frequently diagnosed subtype of non-
Hodgkin's lymphoma (NHL), and more than 50% of cases present in patients over 60 years …

For the past three decades chemotherapy with CHOP (cyclophosphamide/doxorubicin/
vincristine/prednisone) has been the standard treatment for aggressive non-Hodgkin's …

The present study aimed to determine the long-term safety and efficacy of chimeric anti-CD
20 antibody rituxan (rituximab, Biogen IDEC, San Diego, CA, USA; Genentech, South San …

Abstract High-risk Non-Hodgkin lymphoma (NHL) in elderly patients (> 60 yrs) is associated
with a relatively low complete response (CR) rate and a poor overall survival (OS). Previous …